ETFs Allogene Therapeutics, Inc.

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-17 EDT			5-day change	1st Jan Change
1.730 ^USD	+2.37%		-1.70%	+26.28%

09-09	Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM
09-02	Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026	CI

ETFs positioned on Allogene Therapeutics, Inc.

Name	YTD change	Weight	AuM
DIMENSIONAL WORLD EQUITY ETF - USD	+13.64%	-.--%	1,674 M€
SCHWAB U.S. BROAD MARKET ETF - USD	+12.05%	-.--%	44,934 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+17.45%	-.--%	5,739 M€
UBS MSCI USA SELECT FACTOR MIX UCITS ETF (HEDGED TO CHF) A-ACC - CHF	+8.82%	-.--%	28 M€
WISDOMTREE BIOREVOLUTION UCITS ETF ACC USD	+41.76%	1.37%	24 M€
VIRTUS LIFESCI BIOTECH CLINICAL TRIALS ETF - USD	+27.71%	1.07%	50 M€
INVESCO NASDAQ FUTURE GEN 200 ETF - USD	+26.51%	0.48%	23 M€
ALPS MEDICAL BREAKTHROUGHS ETF - USD	+24.42%	0.38%	222 M€
HORIZON KINETICS MEDICAL ETF - USD	+6.88%	0.21%	17 M€
INVESCO RAFI US 1500 SMALL-MID ETF - USD	+16.07%	0.05%	2,894 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF - USD	+23.92%	0.05%	1,079 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF (D) - USD	+23.62%	0.05%	78 M€
ISHARES HEALTH INNOVATION ACTIVE ETF - USD	+12.69%	0.04%	13 M€
ISHARES BIOTECHNOLOGY ETF - USD	+22.69%	0.04%	9,953 M€
VANGUARD RUSSELL 2000 VALUE ETF - USD	+20.08%	0.03%	1,392 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - CAD	-.--%	0.02%	19 M€
INVESCO NASDAQ BIOTECHNOLOGY ETF - USD	+23.70%	0.02%	81 M€
ISHARES RUSSELL 2000 VALUE ETF - USD	+19.60%	0.02%	14,676 M€
ISHARES U.S. SMALL CAP INDEX ETF (CAD-HEDGED) - CAD	+14.68%	0.01%	520 M€
GLOBAL X RUSSELL 2000 ETF (AU) - AUD	+8.82%	0.01%	18 M€
XTRACKERS RUSSELL 2000 UCITS ETF 1C - USD	+17.92%	0.01%	3,050 M€
SCHWAB U.S. SMALL-CAP ETF - USD	+16.99%	0.01%	23,313 M€
GLOBAL X RUSSELL 2000 COVERED CALL & GROWTH ETF - USD	+8.53%	0.01%	9 M€
GLOBAL X RUSSELL 2000 ETF - USD	+16.44%	0.01%	1,540 M€
ISHARES RUSSELL 2000 ETF - USD	+15.95%	0.01%	82,179 M€
GLOBAL X RUSSELL 2000 COVERED CALL ETF - USD	+3.59%	0.01%	1,395 M€
VANGUARD HEALTH CARE ETF - USD	+10.14%	0.01%	19,074 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - CAD HEDGED	-.--%	0.01%	3 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - USD	-.--%	0.01%	0 M€

1 2 3

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Employees

151

Sector

Biotechnology & Medical Research

More about the company